National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
PC-SPES (PDQ®)
Patient Version   Health Professional Version   Last Modified: 09/04/2008



Purpose of This PDQ Summary






Overview






General Information






Laboratory/Preclinical Studies






Animal Studies






Clinical Trials






Adverse Effects






Substitutes for PC-SPES






Overall Level of Evidence for PC-SPES






Changes to This Summary (09/04/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
The Cancer Genome Atlas Reports Brain Tumors Study

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Substitutes for PC-SPES

No substitutes are available for the original PC-SPES. Although manufacturers are selling supplements purporting to be substitutes, the PC-SPES mixture is patented and cannot be duplicated. There are no published reports of clinical trials of herbal mixtures that claim to be substitutes for PC-SPES. The only company that had a license from the patent holder to manufacture PC-SPES is no longer in business, and the product cannot be legally manufactured in the United States without the patent holder’s permission. PC-SPES is not legally available in the United States.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov